Business Context and Reporting Period
Company: GRI Bio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 10, 2025
Reporting Period: Event-based report for December 10, 2025.
Business Context: The Company is an emerging growth company focused on clinical development. This filing reports the issuance of a press release regarding topline results from a Phase 2a clinical trial for the investigational drug GRI-0621 in patients with idiopathic pulmonary fibrosis.
Key Financial Metrics
This Form 8-K is an event-driven report and does not contain audited or unaudited financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity metrics.
Material Changes
The material change reported is the announcement of topline results from the Phase 2a clinical trial for GRI-0621. No financial changes or comparative period data are included in this document.
Guidance, Outlook, and Risks
- Management Commentary: The Company announced topline results for its Phase 2a trial of GRI-0621. Specific details of the results are contained in the attached press release (Exhibit 99.1) and are not summarized in the body of this 8-K.
- Outlook: No specific financial guidance or future operational outlook is provided in this filing.
- Risks and Contingencies: No specific risks or contingencies are detailed in this filing beyond the standard implications of clinical trial results.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for the specific topline data and statistical significance of the GRI-0621 Phase 2a trial results.
- Verify the Company's cash runway and liquidity status in the most recent 10-Q or 10-K, as this 8-K contains no financial data.
- Confirm the next steps for the GRI-0621 program as outlined in the press release.
- Check for any subsequent regulatory filings regarding the interpretation of the trial results.